InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,064.20
(
0.91%
)
US TECH 100
17,173.20
(
1.85%
)
Dow Jones
38,225.66
(
0.85%
)
Brent Oil
83.78
(
0.17%
)
Bitcoin
59,835.79
(
1.21%
)
Post# of 251692
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119554
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 198918

Wednesday, 02/22/2017 11:33:38 AM

Wednesday, February 22, 2017 11:33:38 AM

Post# of 251692
Biocentury write-up on interchangeable FoBs (which mentions MNTA in passing) echoes the comments in #msg-119721999 about why FDA interchangeable status doesn’t matter much for infused (as opposed to self-administered) FoBs:

https://www.biocentury.com/biocentury/regulation/2017-02-13/why-few-biosimilar-companies-may-use-fda%E2%80%99s-proposed-

The full article is behind a paywall, but the free portion is enough to get the gist of it.

p.s. MNTA two disclosed FoB programs are for Humira (M923) and Orencia (M834), both of which can be self-administered.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up